Clinical trial
Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection…
NCT00352833 · Neovii Biotech, Industry · Completed
Key facts
| NCT number | NCT00352833 |
|---|---|
| Title | Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma |
| Official title | Multicenter, Open-Label and Randomized Phase II Study to Evaluate Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients After Curative Resection of a Confirmed Gastric Adenocarcinoma Compared With Surgery Alone |
| Lead sponsor | Neovii Biotech, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Gastric Adenocarcinoma |
| Intervention type | Drug |
| Interventions | catumaxomab |
| Enrollment | 40 |
| Start date | Jul 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Jul 17, 2006 |
| Last update posted | Oct 26, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: